Lantheus to Present New Data on the Effectiveness of Novel PET Cardiac Imaging Agent Flurpiridaz F 18 in Women with Suspected Heart Disease at the American Heart Association 2015 Scientific Sessions
The poster (#4424), “Improved Assessment of CAD in Women with
Flurpiridaz F 18 PET Myocardial Perfusion Imaging: A Subset Analysis of
the Flurpiridaz F 18 301 Phase 3 Study,” will be presented by Gary V.
Heller, M.D., of
The data are from a multicenter, international (
About Flurpiridaz F 18 Injection and Coronary Artery Disease
Flurpiridaz
F 18 injection, a fluorine 18-labeled agent that binds to mitochondrial
complex 1 (MC-1)1, was designed to be a novel myocardial
perfusion PET imaging agent that may better evaluate patients with known
or suspected CAD, which is the most common form of heart disease2,
affecting an estimated 15.4 million Americans 20 years of age or older3.
CAD is the leading cause of death in
About PET and MPI
Positron emission tomography, also called
PET imaging or a PET scan, is a type of nuclear medicine imaging
procedure6 that provides information about the function and
metabolism of the body’s organs, unlike computed tomography (CT) or
magnetic resonance imaging (MRI), which primarily show anatomy and
structure7. MPI is a minimally invasive test that utilizes a
small amount of radioactive material (radiopharmaceutical) injected into
the body to depict the distribution of blood flow to the heart. MPI is
used to identify areas of reduced blood flow (perfusion) to the heart
muscle. The test is typically conducted under both rest and stress
conditions, after which physicians examine and compare the two scans and
predict whether the patient has significant coronary artery disease8.
Although SPECT is most commonly used for MPI9, PET imaging
has gained considerable support and use in the field of cardiovascular
imaging, as it offers many advantages to SPECT, including higher spatial
and contrast resolution, which results in higher image quality and
improved diagnostic accuracy, accurate attenuation correction and risk
stratification10.
About
Safe Harbor for Forward-Looking and Cautionary Statements
This
press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are subject to risks and uncertainties that
may be described from time to time in our filings with the
1 Yalamanchili, P, Wexler, E, Hayes, M, Yu, M, MD, Bozek J, Radeke, H, Azure, M, Purohit, A, Casebier, DS, and Robinson, SP. Mechanism of uptake and retention of 18F BMS-747158-02 in cardiomyocytes: A novel PET myocardial imaging agent. Journal Nuclear Cardiology 2007 Nov-Dec;14(6):782-8.
2
3 Heart Disease and Stroke Statistics. 2014 Update: A Report
From the
4
5
6 Radiology Info. What is Positron Emission Tomography –
Computed Tomography (PET/CT) Scanning. http://www.radiologyinfo.org/en/info.cfm?pg=PET.
Accessed
7
8
9 Salerno, M and Beller, GA, Noninvasive Assessment of Myocardial Perfusion. Circ Cardiovasc Imaging. 2009; 2:412-424.
10 Heller, G, Calnon, D and Dorbala, S. Recent Advances in Cardiac PET and PET/CT Myocardial Perfusion Imaging. J Nucl Cardiol 2009; 16:962-9.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151102006834/en/
Source:
Lantheus Holdings, Inc.
Investor Relations
John
Bakewell, 978-436-7073
or
Media Relations
Meara
Murphy, 978-671-8508